A market worth$1.1 to 2.5 billion,with no product in it.
Every major category in aesthetics has a company that makes the product. Autologous fat transfer, the largest natural volume procedure, has none: the product is the patient's own tissue, so it is delivered entirely as surgery.
Every category has a maker. Except one.
Step 1:
Less than one gram.
A needle biopsy captures the patient's own fat. No liposuction, no operating room.
Step 2:
A thousandfold.
The patient's own cells, expanded roughly 1000× into living, manufactured tissue.
Step 3:
ETB-001.
One manufactured biologic: the patient's own living tissue, in a syringe.
Face
Breast
Body
HandStep 5:
$1.1 to 2.5 billion
One platform across every indication, into a U.S. fat-transfer market delivered until now only as surgery.
Step 4:
The only manufactured fat transfer.
One autologous platform, across every indication.
From bench to the office.
One platform, built in the open — the path from a gram of tissue to a product delivered across every indication.
- 2025
Etienna founded
Founded to manufacture the one aesthetic product no company makes: the patient's own fat.
- Dec 2025
Exclusive license signed
Exclusive rights secured to the core autologous manufacturing technology behind the platform.
- Q1 2026
The ETB-001 platform
Less than a gram of tissue, expanded roughly 1000× into a living, injectable biologic.
- 2H 2026 – 2027
IND-enabling studies
Preclinical safety and manufacturing scale-up underway toward a first-in-human filing with the FDA.
- 2028
First in human
The first clinical study opens, with hand rejuvenation as the lead indication.
- 2030+
Indication expansion
One platform extends across face, breast, and body: every major fat-transfer indication.
Built by people who have taken products through the FDA. Repeatedly.
Robert Lewis
Co-Founder, Chairman
Teva · Sigma · Cypress Pharmaceutical
Missy Clifton, MD
Co-Founder, Chief Medical Officer
Founding partner, Premier Dermatology & Aesthetics
100+ FDA approvals combined, across devices, biologics, and cell therapy.
Guided by leaders in regenerative medicine.
Silvia Corvera, MD
Endowed Chair in Diabetes Research
Professor of Molecular Medicine, UMass Chan Medical School. Pioneer in cellular trafficking, endosomal biology, and adipose tissue function.
Michael P. Czech, PhD
Foxman Chair of Medical Research
Professor Emeritus of Molecular Medicine, UMass Chan Medical School. Foundational work in insulin signaling, adipocyte biology, and metabolic regulation.